Modality
Vaccine
MOA
CD47i
Target
CD3
Pathway
Autophagy
Rett
Development Pipeline
Preclinical
May 2021
→ Jul 2026
PreclinicalCurrent
NCT04209027
1,181 pts·Rett
2024-02→2026-07·Recruiting
NCT07200387
982 pts·Rett
2021-05→TBD·Recruiting
2,163 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-174mo awayInterim· Rett
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Recruit…
Preclinical
Recruit…
Catalysts
Interim
2026-07-17 · 4mo away
Rett
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04209027 | Preclinical | Rett | Recruiting | 1181 | CfB |
| NCT07200387 | Preclinical | Rett | Recruiting | 982 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Miriglumide | Alnylam | Phase 3 | CD3 |